Definitely agree. I'm not quite sure I understand how a dopamine agonist would improve schizophrenia, but the mechanism of action is unique so could be interesting. I definitely want to see any data in bipolar as well.
I'm still thinking Abbvie buyout here. It's such a good fit for them. However, they already own licensing rights to Elagolix so perhaps it's unnecessary. However, I still can see it. The fit is there and Abbvie is throwing huge money behind Elagolix.